| Publications | PubMed=1067619; DOI=10.1073/pnas.73.9.3278
Carey T.E., Takahashi T., Resnick-Silverman L.A., Oettgen H.F., Old L.J.
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.
Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976) PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977) PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977) PubMed=313568; DOI=10.1073/pnas.76.6.2898
Carey T.E., Lloyd K.O., Takahashi T., Travassos L.R., Old L.J.
AU cell-surface antigen of human malignant melanoma: solubilization and partial characterization.
Proc. Natl. Acad. Sci. U.S.A. 76:2898-2902(1979) DOI=10.1007/978-1-4615-7228-2_39
Houghton A.N., Oettgen H.F., Old L.J.
Malignant melanoma. Current status of the search for melanoma-specific antigens.
(In) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston (1981) PubMed=7017212; DOI=10.1093/jnci/66.6.1003
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
J. Natl. Cancer Inst. 66:1003-1012(1981) PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986) PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988) PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991) PubMed=7999427; DOI=10.1016/0959-8049(94)90188-0
Marshall E.S., Matthews J.H.L., Shaw J.H.F., Nixon J., Tumewu P., Finlay G.J., Holdaway K.M., Baguley B.C.
Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays.
Eur. J. Cancer 30:1370-1376(1994) PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H
Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J., McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M., van Zijl P.
Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.
Eur. J. Cancer 31:230-237(1995) PubMed=7747814
Gruis N.A., Weaver-Feldhaus J., Liu Q., Frye C., Eeles R., Orlow I., Lacombe L., Ponce-Castaneda V., Lianes P., Latres E., Skolnick M., Cordon-Cardo C., Kamb A.
Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.
Am. J. Pathol. 146:1199-1206(1995) PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000) PubMed=11016658
Girnita L., Girnita A., Brodin B., Xie Y.-T., Nilsson G., Dricu A., Lundeberg J., Wejde J., Bartolazzi A., Wiman K.G., Larsson O.
Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact.
Cancer Res. 60:5278-5283(2000) PubMed=14871852; DOI=10.1158/0008-5472.can-03-2209
Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J., Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.
Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma.
Cancer Res. 64:1157-1163(2004) PubMed=15299072; DOI=10.1158/1535-7163.895.3.8
Qin J.-Z., Stennett L., Bacon P., Bodner B., Hendrix M.J.C., Seftor R.E.B., Seftor E.A., Margaryan N.V., Pollock P.M., Curtis A., Trent J.M., Bennett F., Miele L., Nickoloff B.J.
p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas.
Mol. Cancer Ther. 3:895-902(2004) PubMed=15467732; DOI=10.1038/sj.onc.1208152
Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J., Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Oncogene 23:8796-8804(2004) PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005) PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006) PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152
Stark M.S., Hayward N.K.
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
Cancer Res. 67:2632-2642(2007) PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x
Johansson P., Pavey S., Hayward N.K.
Confirmation of a BRAF mutation-associated gene expression signature in melanoma.
Pigment Cell Res. 20:216-221(2007) PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009) PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010) PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011) PubMed=21725359; DOI=10.1038/onc.2011.250
Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M., She Q.-B., Gallardo H., Liu C., Merghoub T., Hefter B., Dolgalev I., Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G., Wolchok J.D., Houghton A.N., Solit D.B.
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.
Oncogene 31:446-457(2012) PubMed=22347499; DOI=10.1371/journal.pone.0031628
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
PLoS ONE 7:E31628-E31628(2012) PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012) PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012) PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012) PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013) PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013) PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20.1-20.13(2013) PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625
Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C., Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A., Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F., Rosen N., Solit D.B.
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Cancer Res. 74:2340-2350(2014) PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014) PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014) PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014) PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015) PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015) PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016) PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016) PubMed=27600516; DOI=10.1007/s00262-016-1897-3
Gloger A., Ritz D., Fugmann T., Neri D.
Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
Cancer Immunol. Immunother. 65:1377-1393(2016) PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20.1-20.11(2016) PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019) PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020) PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022) |
|---|
